Yi Wang

FDA investigator

Appears on 4 documents from 2023 to 2024, mostly at sites in California. Most often cites responsibilities of quality control unit (21 CFR 211.22).

4
Documents on file
3.8
Observations per 483
2023
First seen
2024
Most recent

What they cite most

From 15 observations

Activity by year

2023: 3, 2024: 1

Where

California 3 · Pennsylvania 1

Is Yi Wang coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

4 documents, newest first
FirmOpen
483 GlaxoSmithKline LLCSep 25, 2024 · Conshohocken, Pennsylvania
483 Genentech, Inc.Feb 2, 2023 · South San Francisco, California
483 Tanvex BioPharma USA, IncJan 24, 2023 · San Diego, California
483 Form 483 · FEI 3004575449Jan 16, 2023 · San Diego, California

About this profile

What does Yi Wang inspect?

Yi Wang appears on 4 documents on file covering 4 sites, mostly in California.

What do they cite most often?

21 CFR 211.22 (responsibilities of quality control unit), followed by 21 CFR 211.100 and 21 CFR 211.113.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Yi Wang is dated Sep 25, 2024.